MNMohammad Javad Namazi

Mohammad Javad Namazi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Javad Namazi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Guidelines to Innovation: The Evolving Paradigm of Premature Ventricular Complex Management

    by Tannaz Bagheri, Mohammad Ali Akbarzadeh, Mohammad Javad Namazi

    Context: Premature ventricular complexes (PVCs) are among the most common arrhythmias encountered in clinical practice, affecting up to 75% of individuals during prolonged monitoring. However, their management remains unstructured and inconsistent across centers. Recent studies demonstrate that a high PVC burden independently predicts adverse cardiovascular outcomes, including atrial fibrillation, heart failure, and increased mortality. Nonetheless, current therapeutic approaches rely largely on expert judgment rather than on standardized, evidence-based algorithms. Evidence Acquisition: This narrative review synthesized current evidence on the management of PVCs, including their diagnosis, risk stratification, and treatment options. PubMed and major cardiology journals were searched for publications from 2015 to 2025 using terms including "premature ventricular complex," "PVC management," "catheter ablation," and "ventricular ectopy." Recent systematic reviews, meta-analyses, randomized controlled trials, and major clinical practice guidelines, including the 2017 AHA/ACC/HRS and 2022 ESC guidelines, were prioritized. ClinicalTrials.gov was also searched for ongoing trials relevant to the diagnosis and treatment of PVCs. Results: Recent advances in diagnostic imaging, ablation technology, machine learning, and novel pharmacological agents are increasingly challenging traditional management paradigms. In addition, ongoing clinical trials are evaluating innovative therapeutic approaches and standardized protocols. Conclusions: This narrative review synthesizes current evidence on PVC management, discusses recent findings that are reshaping clinical practice, and presents a vision for the future paradigm of PVC care. In this vision, management becomes truly personalized and guided by objective data. This approach may enable improved diagnostic strategies, refined patient selection criteria, and technological innovations that optimize outcomes for patients with PVCs.

  • Open Access

    Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis

    by Reza Eshraghi, Delaram J. Ghadimi, Sara Montazerinamin, Ashkan Bahrami, Yash Kachela, Mahsa Rezasoltani, Mohammad Javad Namazi, Mohsan Subhani, Pouya Ebrahimi, Kaveh Hosseini


  • Open Access

    Curosurf Versus BLES in the Treatment of Preterm Neonates with Respiratory Distress Syndrome: A Randomized Clinical Trial

    by Vahidreza Ostadmohammadi, Mohammad Javad Namazi, Mahsa Rezasoltani, Mohammadreza Sharif, Farzaneh Sharifi, Ahmad Safari, Alireza Sharif

    Background: Two natural surfactants, Curosurf and BLES, are commonly used for the treatment of respiratory distress syndrome (RDS). Animal-derived surfactants have different pharmacological and biochemical features, and these differences might influence their clinical efficacy and complications. Objectives: The present study aimed to compare the clinical effectiveness and complications of Curosurf and BLES in the management of preterm neonates with RDS. Methods: This randomized clinical trial was conducted on 160 neonates with RDS and a gestational age of ≤ 32 weeks. Patients were randomly assigned to two intervention groups to receive either Curosurf (n = 80) or BLES (n = 80). Complications of prematurity, mortality, and the effectiveness of surfactant therapy were compared between the study groups. Results: There were statistically significant differences between the Curosurf group and the BLES group in the length of hospital stay (20.3 ± 14.4 vs. 27.3 ± 18.8 days, P = 0.01), number of surfactant injections (1.2 ± 0.4 vs. 1.4 ± 0.4, P = 0.006), and need for a second dose (21.2% vs. 41.2%, P = 0.005). In terms of complications, both groups showed no considerable differences. Conclusions: Compared to BLES, Curosurf may be more effective in the treatment of preterm neonates with RDS. Further clinical trials with robust designs and long-term follow-up are needed to compare these surfactants.